BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

946 related articles for article (PubMed ID: 18752503)

  • 1. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perforation predicts poor prognosis in patients with primary intestinal diffuse large B-cell lymphoma.
    Chuang SS; Ye H; Yang SF; Huang WT; Chen HK; Hsieh PP; Hwang WS; Chang KY; Lu CL; Du MQ
    Histopathology; 2008 Oct; 53(4):432-40. PubMed ID: 18983608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a "non-germinal center phenotype".
    Kusumoto S; Kobayashi Y; Sekiguchi N; Tanimoto K; Onishi Y; Yokota Y; Watanabe T; Maeshima AM; Ishida T; Inagaki H; Matsuno Y; Ueda R; Tobinai K
    Am J Surg Pathol; 2005 Aug; 29(8):1067-73. PubMed ID: 16006802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 5. Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma.
    Nakamura S; Ye H; Bacon CM; Goatly A; Liu H; Kerr L; Banham AH; Streubel B; Yao T; Tsuneyoshi M; Savio A; Takeshita M; Dartigues P; Ruskoné-Fourmestraux A; Matsumoto T; Iida M; Du MQ
    Clin Cancer Res; 2008 May; 14(10):3002-10. PubMed ID: 18445693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
    Obermann EC; Csato M; Dirnhofer S; Tzankov A
    J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
    Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
    Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
    Le Gouill S; Talmant P; Touzeau C; Moreau A; Garand R; Juge-Morineau N; Gaillard F; Gastinne T; Milpied N; Moreau P; Harousseau JL; Avet-Loiseau H
    Haematologica; 2007 Oct; 92(10):1335-42. PubMed ID: 18024371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
    Liu YH; Xu FP; Zhuang HG; Lai KC; Xie D; Luo DL; Li L; Luo XL; Xu J; Zhang MH; Zhang F; Li HM
    Hum Pathol; 2008 Jun; 39(6):875-84. PubMed ID: 18440593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.
    Barrans SL; Evans PA; O'Connor SJ; Kendall SJ; Owen RG; Haynes AP; Morgan GJ; Jack AS
    Clin Cancer Res; 2003 Jun; 9(6):2133-9. PubMed ID: 12796378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.
    Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y
    Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 14. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients.
    Amen F; Horncastle D; Elderfield K; Banham AH; Bower M; Macdonald D; Kanfer E; Naresh KN
    Histopathology; 2007 Jul; 51(1):70-9. PubMed ID: 17593082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
    Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
    J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation.
    Costa LJ; Feldman AL; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Ansell SM
    Br J Haematol; 2008 Jul; 142(3):404-12. PubMed ID: 18492096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
    Barrans S; Crouch S; Smith A; Turner K; Owen R; Patmore R; Roman E; Jack A
    J Clin Oncol; 2010 Jul; 28(20):3360-5. PubMed ID: 20498406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevalence of germinal center B-cell-like and non-germinal center B-cell-like types of diffuse large B-cell lymphoma in Shanghai, China].
    Chen Y; Chen H; Fu K; Zhu XZ; Irons R
    Zhonghua Bing Li Xue Za Zhi; 2010 May; 39(5):313-8. PubMed ID: 20654154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.